Quick Answer
Axsome Therapeutics, Inc. reported Diluted EPS of $3.68 per share (loss) for fiscal year 2025.
Axsome Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.68 | +38.6% |
| 2024 | -$5.99 | -13.7% |
| 2023 | -$5.27 | -14.6% |
| 2022 | -$4.60 | -32.6% |
| 2021 | -$3.47 | -25.3% |
| 2020 | -$2.77 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.94 | +29.9% | +3.1% |
| June 30, 2025 | -$0.97 | +41.9% | +20.5% |
| March 31, 2025 | -$1.22 | +15.3% | +9.0% |
| September 30, 2024 | -$1.34 | -1.5% | +19.8% |
| June 30, 2024 | -$1.67 | -8.4% | -16.0% |
| March 31, 2024 | -$1.44 | -453.8% | -9.1% |
| September 30, 2023 | -$1.32 | -23.4% | +14.3% |
| June 30, 2023 | -$1.54 | -45.3% | -492.3% |
- Axsome Therapeutics, Inc. showed an increase of +38.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Axsome Therapeutics, Inc.’s diluted eps has declined by 32.9% (from $2.77 per share (loss) to $3.68 per share (loss)).
- The most recent figure is from Axsome Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: